Image of the Month

Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment

Disclosure: Dr. Hida has received grants and personal fees from Ono Pharmaceutical Co. Ltd., Astra Zeneca, Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb, MSD, Novartis, Nippon Boehringer Ingelheim, Eli Lilly, Taiho Pharmaceutical Co. Ltd., Pfizer, Clovis Oncology, Kissei, and Ignyta; and has received grants from Eisai, Takeda Pharmaceutical Co. Ltd., Dainippon Sumitomo Pharma, AbbVie, Merck Serono, Kyowa Hakko Kirin, Daiichi Sankyo, Astellas, and Servier. The remaining authors declare no conflict of interest.